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Despite the use of antibiotics and vaccines, the frequency of respiratory tract infections is still high and these
infections interest a wide range of patients, from children to aged people, including in particular these extreme
categories because of the deficiency of their immune system, due to immaturity in the former case and to
“immunosenescence” in the latter. For that reason immunostimulant drugs are getting more important to prevent
and to attenuate infections. Pidotimod (3-L-pyroglutamyl-L-thiazolidine-4carboxylic acid) is a synthetic dipeptide
with immunomodulatory properties. We reviewed studies conducted on different categories of patients, with
particular attention on children and senile patients suffering from recurrent respiratory tract infections, associated,
or not, with asthma or COPD. The outcomes considered are both clinical and laboratory parameters. The common
end-point of these studies is that Pidotimod has an immunomodulatory activity which is able both to improve the
clinical conditions of patients and to enhance and stimulate their immunity cells (lymphocytes but not only)
functions acting on adaptive and innate immunity. Pidotimod is also able to increase the concentration of salivary
IgA directed against bacteria; furthermore, it can modulate airway epithelial cells functions up-regulating the
expression of toll-like receptors and acting on adhesion molecules. According to studies conducted on patients
with atopic asthma, it seems that Pidotimod could affect T-lymphocytes balance with a possible addictional
anti-allergic activity. Furthermore, it has been demonstrated an improvement of FEV1 and PEF in asthmatic patients
treated with Pidotimod. Main clinical outcomes are the reduction of the number of infectious episodes, lesser
severity of signs and symptoms and, consequently, a reduction in use of antibiotics and symptomatic drugs, less
working and school days lost, less mortality and morbidity. The studies considered give positive results, confirming
Pidotimod’s efficacy. Furthermore, many studies show a good safety profile of the drug, without recording serious
adverse events and mutagenic potential, and a very low incidence of side effects. Pidotimod is also a more safe
solution in patients subjected to vaccination, if compared to lyophilized polibacterial, which can’t be administered
for thirty days before vaccination.
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Acute respiratory tract infections (ARTIs) were called by
some authors, and still are, the “forgotten pandemics”.
At present, despite the introduction of new antibiotics
and vaccines which contribute to reduce the risk of mortal-
ity and morbidity, they remain widespread and affect both
young and elder people. Furthermore, the socio-economic
burden of ARTIs remains high, considering the cost of
symptomatic drugs, antibiotics, hospitalization and the in-
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unless otherwise stated.In particular, viruses are the main agents responsible
of ARTIs in the pediatric age but the high number of
circulating viruses and their different sub-types, besides
the environmental risk factors, are not the only factors
contributing to the incidence of ARTIs in the first years
of life. In fact, the immaturity of the immune system in
children maintains a considerable role. That’s why a
functional approach to preventing and treating ARTIs is
increasing the immune response or enhancing the child’s
innate defence mechanisms [1].
Also in elder people there is a deficiency in the func-
tion of immune system, which leads to frequent infec-
tions, in particular of respiratory tract, and to COPD
(chronic obstructive pulmonary disease) exacerbations.
The immune system, in fact, during senile age goesl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Pidotimod: mechanism of action.
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senescence” and still matter of study, which lead to a
lower ability to respond to infections and to develop im-
munity after vaccination [2].
Since the early 90’s a wide scientific production has been
published about Pidotimod, a new immunostimulant drug.
Its efficacy has been tested both in children and in adults,
with a focus of interest on respiratory tract infections, in
particular as a complication of asthma and chronic
obstructive pulmonary disease.Review
The immunomodulating activity of Pidotimod
In the last years different kinds of immunostimulants of
natural or synthetic origins and working with different
mechanisms have been created for the prevention of
ARTIs. Pidotimod (3-L-pyroglutamyl-L-thiaziolidine-4
carboxylic acid) is a synthetic dipeptide molecule with
immunomodulatory properties [1].
In vivo and in vitro studies shows that Pidotimod’s
immunomodulatory activity is focused on both adaptive
and innate immunity. Pidotimod induces dendritic cells
(DCs) maturation, up-regulates the expression of HLA-
DR and of co-stimulatory molecules, stimulates DCs to
release pro-inflammatory molecules driving T-cells pro-
liferation and differentiation towards a Th1 phenotype,enhances natural killer (NK) cells functions and pro-
motes phagocytosis [3].
Recent studies remark the immunomodulating role of
Pidotimod: this molecule is able to improve the response
to inflammatory stimuli acting on different immuno-
logical pathways (Figure 1).
Airway epithelial cells and mucosal immune cells have
a crucial role against viral lower respiratory tract infec-
tions, controlling the virus and the development of
inflammation and disease through innate responses, mu-
cosal IgA responses and proinflammatory cytokines,
chemokines and growth factors [4]. The “mucosal asso-
ciated lymphoid tissue” (MALT) is a highly comparti-
mentalized immunological system in which immune
responses are governed by the nature of pathogen, the
type of antigen-presenting cells involved (such as
dendritic cells) and the local environment. It has been
demonstrated that Pidotimod is able to induce DCs
maturation and releasing of cytokines, to up-regulate the
expression of HLA-DR and different co-stimulatory mol-
ecules [5]. An analysis of the antigen-specific salivary
IgA levels has been conducted in patients (both adults
and children) with frequent upper respiratory tract in-
fections (due to Klebsiella pneumoniae, Staphylococcus
aureus, Streptococcus pyogenes, Moraxella catarrhalis,
Haemophilus influenzae and Streptococcus pneumoniae).
Salivary fluid was collected and the presence of
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surface antigens of bacteria) was evaluated. The starting
point of the study is the hypothesis that recurrent re-
spiratory infections could be associated with secretory
IgA deficiencies. The results show that both in adult
and young population there wasn’t a good immune re-
sponse, with low antibody titres and a very small number
of patients with a strong IgA-mediated immune response.
In all cases, immune response was directed only to one or
two microbes. After treatment with an immunostimulant
(a polyvalent bacterial mechanical lysate in this case) a sig-
nificative number of patients experienced an enhancement
of the concentration of salivary IgA directed against the
bacteria considerated in the study (with a predominant role
of IgA against Klebsiella pneumoniae) [6].
Finally, a research on microbiota reveals, through a
study on TLR-7 role in respiratory influenza A virus in-
fection in animals under antibiotic/probiotic treatment,
the importance of a well-balanced intestinal flora in
regulating immunity in respiratory mucosa through the
up-regulation of the TLR-7 signaling pathway [7].
An Italian research demonstrates how Pidotimod can
modulate airway epithelial cells functions, which play a
primary defensive role both providing a physical barrier
and being involved in innate and adaptive immune
responses; Pidotimod, in fact, is able to upregulate the
expression of toll-like receptor-2 (TLR-2) on airway epi-
thelial cells, beside important effects on intercellular ad-
hesion molecule (ICAM-1), IL-8 release and others. TLR
plays a key role in the innate immune system: it’s a type
of pattern recognition receptor and recognize molecules
broadly shared by pathogenes but distinguishable from
host molecules, collectively referred to pathogen-
associated molecular patterns (PAMPs) [8]. Further-
more, it has been demonstrated that Pidotimod can
also modulate the inflammatory cascade triggered by
TLR ligands through the up-regulation of the nucleo-
tide binding and oligomerization domain receptor
(NOD-like receptor) NLRP12 [9].
Pidotimod in children
Up to now, clinical studies on Pidotimod have been
mainly conducted on children, focused on prevention of
respiratory tract infections. The results show benefits
from that therapy in many aspects of respiratory tract
infections: a reduction of the number of infections, less
day of fever, a lesser severity of signs and symptoms, and
consequently a reduction in use of antibiotics and
symptomatic drugs. Furthermore, the trials suggest that
Pidotimod is a simple, well-tolerated and safe approach
to reduce risks and symptoms correlated to respiratory
tract infections [1] (Table 1).
A study proposed in 2012 by Zhou and Dai compares
responses of children with recurrent respiratory infections(RRI) to treatment with Pidotimod or spleen aminopep-
tide (a cell immunity enhancer made of peptides and
nucleotides extracted from spleen of healthy animals),
investigating their effect on Th1/Th2 cytokines balance. In
fact, according to recent study in immunology, a func-
tional disorder of Th1/Th2 cells, and more generally an
immune hypofunction, could be strictly related to devel-
opment of RRI in children. Children, divided into two ran-
domized groups, received “Pidotimod oral solution” or
“Spleen aminopeptide oral solution” in addition to routine
treatment. The outcomes were clinical evolution of myco-
plasmal pneumonia and the levels of inteleukin-4 and
interferon-γ before and after treatment. It’s appropriate to
remember that TH1 cells, which mainly mediates cell im-
munity, inflammatory reactions and delayed hypersensiv-
ity, are dependent on IFN-γ, while Th2 cells, involved in
humoral immunity, works with dependence on IL-4. Pido-
timod was able to down-regulate secrection of IL-4 and to
enhance secretion of IFN-γ and other Th1 cytokines such
as IL-12, thereby modulating Th1/Th2 cytokines balance;
spleen aminopeptide too was able to regulates the levels of
each T-cell subgroup and to enhance anti-infection ability
but the study shows a statistically significant better func-
tioning of Pidotimod [10].
A recent Italian study conducted on 100 children with
at least six recurrents of respiratory tract infection in a
year and at least three involving lower airways confirms
that the administration of Pidotimod is able to reduce
the symptoms of upper and lower respiratory tract, the
use of medications, the loss of school days and pediatric
visits for RRI [11].
Another significant trial has been conducted on
children with Down’s Syndrome, which frequently ex-
perience acute respiratory tract infections (ARTIs) be-
cause of the associated immune defects of both specific
and non-specific immunity. All children received a single
dose of virosomal-adjuvanted influenza vaccine (Flu).
Flu-specific IgG1 and IgG3 levels in plasma samples
were determined pre- and post-vaccination, observing a
significative upregulation of genes involved in activation
of innate immune system and in antimicrobial activity in
the group treated with Pidotimod [3].
Another study conducted on children with Down’s
Syndrome shows Pidotimod’s effects from a clinical point
of view. Twenty-six children with Down’s Syndrome were
divided in two groups: the former (group A) received a
treatment with Pidotimod and the latter (control group)
was untreated. The follow-up showed that the clinical
conditions were significantly improved in “group A”, in
particular nasal secretions, nasal obstruction and mu-
cosal hyperemia decreased. Parents clinical diaries too
showed less recurrent inflammatory episodes and days
of fever and, moreover, a cut in the use of antibiotics
and antipyretics [12].
Table 1 Pidotimod: clinical trials in children
Prophylaxis with the novel immunomodulator Pidotimod
reduces the frequency and severity of upper respiratory
tract infections in children with Down’s Syndrome




• M/F = 12/12 ↓ mucosal hyperemia
• From 3 to 13 years ↓ less recurrent
inflammatory episodes
↓ days of fever and,
↓ in the use of antibiotics
and antipyretics.
Immunomodulating activity of Pidotimod in children with
Down Syndrome.
18 children ↑ activity of vaccine when
co-administration
• M/F = 14/4
• From 3 to 10 years
Changes of immune function in children with refractory




↓ of number of recurrence ↑ the number of T
cells
↓ duration of symptoms ↑ the number
↓ duration of antibiotics
treatment
natural killer cells
Comparison of effects of Pidotimod and spleen aminopeptide on
clinical symptoms and Th1/Th2 cytokines in children with RRI
86 children with recurrent
respiratory infection
↓duration of symptoms ↓levels of inteleukin-4
↑levels of INF γ
• M/F = 44/42 ↓ day of treatment
• Mean age control group
2.9 years
• Mean age treatment
group 3.2 years
Observation of impact and efficacy of Pidotimod on serum
interleukin-4 and gamma-interferon levels in children with asthm
52 children ↓levels of inteleukin-4
↑levels of INF γ
• Treatment group M/F =
20/16 mean age 9.2 years
• Control group M/F = 18/18
mean age 8.7 years
The effect of Pidotimod in the prevention and Treatment of
Pediatric Bronchial Asthma
100 children ↑ phagocytic activity
• treatment group M/F = 29/




• Control group M/F = 26/24




The effect of Pidotimod on serum IL-4, IFN-gamma and IgE
in asthmatic children
80 children ↓level of IL-4,
• Treatment group M/F =
24/16 from 6 to 9 years
↓IgE level
↑level of IFN-gamma
• Control group M/F = 23/17
from 6 to 9 years
Immune modulator Pidotimod decreases the in vitro expression
of CD30 in peripheral blood mononuclear cells of atopic asthmatic
and normal children.
22 children down-regulate CD30
+
• M/F = 14/8
• mean age 6.2 years
Pidotimid may prevent recurrent respiratory infections in children 100 children ↓ the symptoms of upper
and lower respiratory tract,
• M/F = 49/51 ↓ the use of medications,
↓ loss of school days
• Mean age 4.9 years ↓ pediatric visits for RRI
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tract infections in children. A study conducted in 2002
inquired children with refractory Mycoplasma Pneumo-
niae pneumonia (MMP). The children were divided into
three groups: 66 patients with refractory pneumonia, 40
with common MMP and 18 healthy controls. The first
group was further divided into two parts: one received a
treatment with oral azythromicyn plus pidotimod, while
to the other set was administered only the antibiotic. In
children with refractory MPP levels of CD3+, CD16+,
CD56+ and CD4+/CD8+ ratio were lower than in com-
mon MPP and control groups. The results demonstrated
that Pidotimod increases the number of T cells and natural
killer cells and in clinical practice, during a follow up of six
months, the study showed a decrease of number of recur-
rence and of the duration of symptoms and antibiotics
treatment, in the group treated with Pidotimod [13].
Finally, we must remember that patients with atopic
asthma are more susceptible to viral infections of re-
spiratory tract. About this issue, an interesting study has
been conducted on 22 children with mild atopic asthma
and a control group of 9 children with negative history
of asthma. The study investigated Pidotimod’s effect on
peripheral blood mononuclear cells. Pidotimod was able
to down-regulate the expression of CD30+ cells in both
asthmatic and normal children. Considering of the asso-
ciation of CD30 with Th2-cells, this study supports the
possibility that Pidotimod could affect the Th1/Th2 bal-
ance in atopic asthma with a possible additional “antial-
lergic” activity of the drug [14].
Pidotimod’s efficacy has been tested not only in
children with respiratory tract’s pathologies but also in chil-
dren with other immunity disorders, such as Henoch-
Schonlein Purpura (HSP), with positive results. A study
demonstrates that Pidotimod is effective for prevention of
relapse of HSP thanks to an accelerated recovery of HSP
immune abnormality, that consists in high serum concen-
tration of IgA and low levels of CD3, CD4 and low CD4/
CD8 ratio [15].
Pidotimod can also regulate the immunity functions in
paediatric patients with nephrotic syndrome (NS), pre-
venting the relapse rate of the disease as seen in a study
conducted in 2009. The study observed children with
NS for twelve months, revealing a lower relapse rate
in treated patients treated than in the control group.
Moreover, during treatment the CD4+ T cells increased
significantly in children who received Pidotimod, with a
concomitant decrease of CD8+ and a normalization of
CD4+/CD8+ rate [16].
As said before, Pidotimod seems to have a beneficial ef-
fect and a good tolerability in children with pathologies due
to immunological disfunctions, but further studies and lar-
ger sample size are still needed because the heterogeneity
of the trials (in terms of sample size, age of subjectrecruited, confounding factors, duration of the intervention
and misused statistical tests) is high and the possibility of
publication bias can’t be escluded [3].
Pidotimod in adults
It’s possible to find studies of Pidotimod also in adult pa-
tients with persistent or recurrent upper respiratory tract
infections.
In 1995 the equipe of Prof. Zardo (Policlinico Umberto
I, Rome) selected a group of fourty patients, adults and
children, with recurrent pharingotonsillitis (at least five
episodes with fever) in the last year. The treatment
group received Pidotimod for sixty days while the con-
trol group received lyophilized polybacterial (LPV). After
ninety days the patients in the first group showed a sig-
nificantly increase of immune-response on Multitest
(which consists in intradermical inoculation of seven
different antigens and observation of cutaneous re-
sponse); it means that the patients treated with Pidoti-
mod showed an increase of number and dimension of
positive cutaneous response. The groups were also di-
vided into two further categories: patients with or with-
out recurrent of upper respiratory tract infection after
three months of observation. The 65% of people who re-
ceived Pidotimod hadn’t recurrent versus the 25% of the
patients who received LPV [17].
In 2004 a study considered the use of Pidotimod in se-
nile pneumonia. One set of patients received antibiotics,
expectorants and Pidotimod, the other group received
only the classic treatment. The results showed a signifi-
cantly different outcome between the two groups, with a
better clinical progress and immunological response in
treatment group, while there wasn’t a significative differ-
ence in the number of patients with or without bacterial
eradication between the two groups [18].
Pidotimod’s efficacy in elder people has been also stud-
ied after “ex vivo” administration in healthy subjects. An
Italian study confirms that Pidotimod is able to improve
proliferation of T-cells in a group of elderly patients (se-
lected as a model of immunodeficiency because of the
changes of the immune function that usually happen in
aged people), as seen before in previous study conducted
on model of age-associated immunodeficiency [19].
Effect of Pidotimod has been proven not only in re-
spiratory tract infections affected people but also in pa-
tients with genital and urological infections, such as
recurrent genital herpes, non-gonococcal urethritis and
serofast syphilis [20-23].
Also in Human Papilloma Virus (HPV) genital infec-
tion, which causes vulvar papillomatosis, a treatment
with Pidotimod is able to lead to a regression of the pap-
illomatous lesions, with better results if compared with a
control group treated with placebo. Furthermore, the ef-
ficacy of Pidotimod against HPV genital lesions seems
Table 2 Pidotimod: clinical trials in adults
Study Population Clinical outcome Laboratory outcome
Evaluation of the efficacy of Pidotimod in the exacerbations
in patients affected with chronic Bronchities
181 COPD ↓Frequency of
relapses
Expectoration characteristics
• M/F = 117/64 ↓ to time of relapses, ↑ spirometric parameters
Mean age 62.5 years ↓ time of recovery
Pidotimod activity against chronic bronchitis exacerbation 580 COPD ↓ fewer infectious
exacerbations
• Treatment group M/F = 94/31
mean age 66.2 years
↑ better response to
antibiotics treatment
↓days out of work• Placebo treatment M/F = 200/63
mean age 65.2 years
Immunological function of T-lynphocyte in the elderly with
chronic obstuctive pulmonary disease during acute
exacerbations medication intervention
103 COPD ↓day of
hospitalization
↑ the cell immune response
in elderly patients
• Elderly COPD intervention group




• Elderly COPD control group M/F =
22/12 mean age 69.9 years
• Non elderly COPD control group
M/F = 15/10 mean age 56.2 years
Ex vivo evaluation of Pidotimod activity in patients with
chronic obstructive pulmonary disease.
52 COPD ↑T-cells activity ↑stimulate
macrophages and
granulocytes• Treatment group
M/F = 13/13 mean age 65.92
• Control group M/F = 10/16 mean
age 62.46
Treatment of 30 cases of senile pneumonia with
Pidotimod.
62 elderly with pneumonia ↓n° of recovery ↑ neutrophilic bactericidal
↑ bacterial
eradication
↑ IgG level• M/F = 33/29
• Mean age 72 years
Valutazione dell’attività del Pidotimod sulla secrezione di
IgA in pazienti affetti da BPCO
20 COPD ↑of secretory IgA in the
sputum,
• From 40to 75 years
a stabilization of the level.
Valutazione sperimentale controllata dell’attività di
Pidotimod in paziente affetti da BPCO
85 COPD ↓ number of
exacerbations
• M/F = 54/31
Pidotimod activity against chronic bronchitis exacerbations 580 COPD ↓number of
infectious
exacerbations
• Treatment group M/F 94/31
mean age 66.2 years
↓duration of
Exacerbations
↓duration of therapy• Control group
M/F = 200/63 mean age 62.46
years
Naturally occurring immune response against bacteria
commonly involved in upper respiratory tract infections:
analysis of the antigen-specific salivary IgA levels.
21patients ↑of the concentration of
salivary IgA
• M/F = 12/10
• mean age 41 years
Treatment of 30 62 patients ↓ number of
hospitalization
↑ neutrophilic activity
cases of senile pneumonia with Pidotimod • M/F = 33/29 ↑level of IgG
• Mean age 72 years
Pidotimod nel trattamento delle faringotonsilliti recidivanti 40 adults + children with recurrent
pharingotonsillitis
↓ recurrent of upper
respiratory
↑ of immune-response on
Multitest
• M/F = 13/21
• Mean age 23.2 years
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ter safety profile [24]. Immunosuppression is, in fact, a
risk factor for HPV infections and related pathological
conditions and it’s clear the importance of a comple-
mentary immunostimulatory treatment, beside cryother-
apy or laser therapy, to reduce the risk of recurrences. It
has been also demonstrated that the combination of
Pidotimod and vitamin C has a certain efficacy against
female genital warts [25].
In literature it’s possible to find a study on the effects
of Pidotimod on immune function in patients with
chronic hepatitis C. In these patients the diagnosis of
chronic hepatitis C is in according to the diagnostic cri-
teria revised in the “Fifth National Conference on Conta-
gious and Parasitic Disease”. The study compares two
groups, twelve cases of healthy individual and fourty-six
patients with chronic hepatitis; Pidotimod is adminis-
tered 800 mg once a day for 1-2 months. The results
show that IL-2, IL-4 and IL-6 increased significantly in the
treatment group, but there is no evidence that Pidotimod
can improve the expression of IFN-γ in both groups; more-
over, the ratio of Th1/Th2 decreased in treatment group.
In summary, the study demonstrated that Pidotimod is
able to improve the expression of Th1 cytokines and in-
creases the cellular immune function and viral clearance
ability of the host [26] (Table 2).
Pidotimod in asthma
Asthma is a common chronic inflammatory disease of the
airways characterized by variable and recurring symptoms,
reversible airflow obstruction and bronchospasm. Common
symptoms include wheezing, coughing, chest tightness, and
shortness of breath. Asthma is thought to be caused by a
combination of genetic and environmental factors. It is
clinically classified according to the frequency of symptoms,
forced expiratory volume in one second (FEV1), and peak
expiratory flow rate. Asthma may also be classified as atopic
(extrinsic) or non-atopic (intrinsic) where atopy refers to a
predisposition toward developing type 1 hypersensitivity
reactions.
Thanks to many studies conducted in the last years is
now clear that there is a relationship between the expos-
ure to viral pathogens and the development of allergic
diseases but in this context viruses seem to be “a
double-edged sword”, as affirmed in the past. In fact,
while environmental exposure to some viruses has been
associated with an increased resistance to allergic dis-
eases, on the other hand we can observe that severe re-
spiratory viral infections during childhood increase the
risk of a subsequent development of asthma [27].
In regard to that, we should remember the “hygiene
hypothesis”, which states that a lack of early childhood
exposure to infectious agents, symbiotic microorganisms
(e.g. gut flora or probiotics), and parasites increasessusceptibility to allergic diseases by suppressing the nat-
ural development of the immune system. In particular,
the lack of exposure is thought to lead to defects in the
establishment of immune tolerance.
We can affirm that the pathogenesis of asthma is the
result of many combined factor, in particular Th1/Th2
cytokine imbalance, IgE-dependent immediate type
hypersensitivity reactions and eosinophilic infiltration medi-
ated by overactive Th2 cytokine responses. Interleukine-4
(IL-4) inhibits production of interferon-γ (IFN-γ), promotes
local airways inflammation and development and progres-
sion of asthma; IFN-γ, on the other hand, has an opposite
role, protecting from these inflammatory mechanisms
which lead to asthma. Therefore, correcting the cytokine
imbalance by regulating IL-4 and IFN-γ seems to be a
promising approach to the treatment of asthma in
children [28].
Clinically, asthma can be stable for weeks or even
months but acute exacerbations can be caused by many
triggering agents: among others, both viral and bacterial
infections of the upper respiratory tract can lead to a
worsening of the disease.
It’s now clear the importance of prevention of chronic
lung diseases, like asthma. According to the “NHLBI
Workshop on the Primary Prevention of Chronic Lung
Disease”, there are three kind of intervention to be
tested in clinical trial now or in the future: preventing
asthma through prophilaxis against respiratory syncytial
viruses and human rhinovirus infections of the airways;
immune modulation, using prebiotics, probiotics and
bacterial lysates; and prevention of allergen sensitization
and allergic inflammation using anti-IgE [29].
A study conducted by Zhai in 2011 shows the immu-
nomodulator effect of Pidotimod in prevention and
treatment of pediatric bronchial asthma. In that study
the frequency, degree and duration of asthmatic attack
were observed after treatment and markers of immuno-
logical response were measured before and after treat-
ment. Asthma is closely associated with CD4+/CD8+
imbalance and the use of CD4+ cells as a target point of
immune regulation in asthma have been proposed. The
study shows that Pidotimod can increase the phagocytic
activity and chemotaxis of macrophages and neutrophilis,
activate natural killer cells and promote mitosis-induced
proliferation of lymphocites in order to restore normal
values of low CD4+ and a normal CD4+/CD8+ ratio. It’s
important to underline that during the clinical observation
period none of the children experienced a serious adverse
drug reaction, indicating that the drug has good safety [30].
Other similar studies exist and confirm the role of
Pidotimod on IL-4 and IFN-γ in children with asthma.
A clinical trial conducted by Ma and Sun in 2011, besides
confirming the efficacy of Pidotimod against cytokines
imbalance, shows its action on IgE level, which decreases
Ferrario et al. Clinical and Molecular Allergy  (2015) 13:8 Page 8 of 10significantly after the treatment. In addition to this im-
portant outcome, the study shows an improvement in pul-
monary function data, such as forced expiratory volume
in 1 second (FEV1) and peak expiratory flow rate (PEF) in
treatment group if compared with control group [31].
Pidotimod in COPD
Chronic obstructive pulmonary disease (COPD) is one
of the main causes of morbidity, hospital admission and
loss of working day in industrialized countries. COPD is
a type of obstructive lung disease characterized by
chronically poor airflow with not reversible obstruction
at spirometry. Its clinical features include shortness of
breath, cough, sputum production and the typical flares,
characterized by a worsening of breathing difficulties
and cough and purulent sputum. These exacerbations
are often due to respiratory tract infections.
Pidotimod has been tested in patients with an infec-
tious relapse of COPD in a double-blind randomized
trial and the results indicate that it’s significantly more
effective than placebo, in relation to time and frequency
of relapses, as well as expectoration characteristics, time
of recovery, spirometric parameters and laboratory tests.
According to literature, in fact, Pidotimod stimulates
cell-mediated immunity and the study confirms the re-
sults obtained by many authors, who affirmed that
Pidotimod acts on cell-mediated immunity increasing
mitogen-induced lynfocites blastogenesis, potentiates
rosette activity, activates macrophages potentiating
chemotaxis and superoxide anion production and pro-
tects against experimentally induced infections [32].
Anyway, this is not the only study which investigates
the role of Pidotimod in exacerbations of chronic bron-
chitis. In particular, some Italian trials focus on this
issue, comparing Pidotimod-treated patients with con-
trol patients (treated with placebo). The results show an
enhancement of clinical (in particular fewer infectious
exacerbations and better response during acute infec-
tions) and immunological parameters both during the
treatment and during the follow-up period, suggesting a
protective action of the drug and the possibility of the
use of Pidotimod in cyclic therapy [33]. Pidotimod in
fact is able to potentiate T-cells activity not only during
treatment but also after the end of therapy (till five
weeks) and to stimulate macrophages and granulocytes,
as demonstrated in other trials [34].
In literature we can also find a study in elderly with
chronic obstructive pulmonary disease with COPD exac-
erbations. The study investigated the role of Pidotimod
demonstrating that it’s able to improve the cell immune
response in elderly patients with COPD flares who have
a suppressed T-cell immune response if compared
with patients of the same age in the healthy group and
with those in the non-elderly COPD control group. Thecauses of the initial abnormality of T-cells in patients
with COPD can be ascribed to malnutrition, long-term
smoking, repeated bacterial or viral infections, glucocor-
ticoids therapy and severe hypoxemia [35].
The exacerbations of COPD are proportional to the se-
verity of disease (which is strictly related to FEV1 decline).
An Italian study evaluated eighty-five patients with severe
COPD (GOLD 3 stage) divided into two groups: the former
received a vaccine against influenza virus plus Pidotimod,
the latter received only the vaccine for 4 months. The out-
comes of the study were the number of patients with ex-
acerbation and the number of exacerbations for each
patient. The results show a significant difference between
the two groups of patients in terms of number of exacerba-
tions, with a reduction of exacerbations in treatment group.
Instead, there was no significant difference in the duration
of the symptoms of exacerbation between the two groups.
Furthermore, Pidotimod represents a more safe solution for
patients subjected to vaccination who need an immunosti-
mulant treatment, in particular if compared to lyophilized
polibacterial, which can’t be administered for 30 days
before vaccination [36].
Focusing on bacterial exacerbations, we must remem-
ber a study conducted on patients divided in two groups
and treated with Pidotimod plus Augmentin or placebo
plus Augmentin. In this case too, the efficacy of Pidotimod
has been shown by a faster remission of symptoms and a
higher number of positive responses to skin test (testing
immunocompetence) in the former group. Furthermore,
the safety of the drug has been confirmed one more time,
with a very low incidence of side effects [37].
An old study shows that the use of Pidotimod, if com-
pared with placebo, increases the secretory IgA in pa-
tients with COPD; in particular twenty patients were
selected and were treated with the drug for 4 weeks and
observed during a follow-up period of 2 weeks. The level
of secretory IgA was assessed before, during and after
the treatment, and also the viscosity and the elasticity
of sputum was assessed. The result showed that the pa-
tients treated with Pidotimod had a significant increase
of secretory IgA in the sputum, and also a stabilization
of the level. During the follow up was observed a linear-
ity inclination to the physiological value of secretory
IgA. In conclusion Pidotimod, during the stabilization
phase, supports a good protection to the infection
because IgA activate the complement system and
decrease the bacterial bond to the mucosal surface. On
the other hand, data related to viscosity and linearity of
sputum didn’t change significantly between the two
groups [38].
Pharmacology
Pidotimod has been investigated in different pharmaco-
kinetic studies in healthy volunteers.
Ferrario et al. Clinical and Molecular Allergy  (2015) 13:8 Page 9 of 10The studies show that plasma levels of Pidotimod
after parenteral administration follow a second order
pharmacokinetic while after oral administration follow
a first order pharmacokinetic. The molecule is early
absorbed and its half-life is approximately four hours.
The oral bio-availability is 42-44%; the compound is
eliminated unchanged through urines without being
metabolized. Plasma clearance is 5 l × hE-1, and the
apparent distribution volume is 30 liters, so it is not
shown accumulation neither auto-induction phenomena.
It has also been demonstrated that the different oral
formulations (tablets, sachets and vials) are bioequivalent
[39].
A study conducted on mice investigates the use of
Pidotimod in “water-in-oil-in-water” (W/O/W) double
emulsion (hydrophilic bioactive substances stored into
droplets encapsulated by an oil coating) as a delivery
system with an enhanced oral bioavailability, higher than
Pidotimod control solution. The results of the study
confirm the initial hypothesis and, moreover, suggests an
extra absorption pathway for W/O/W emulsion because
the plasma concentration peaking time is significantly
prolonged. Furthermore, the plasma half-life is prolonged
and the elimination is slowed. These results suggest a differ-
ent absorption mechanisms of W/O/W, which may be
absorbed into lymphatic circulation through the cycle role
of bile [40].
In the end, we can affirm that Pidotimod has a good
safety because it has shown a very good safety in pretty
much all the studies, with a low risk of collateral effects
and, moreover, we should remember a study conducted
on mice which shows that Pidotimod has not mutagenic
potential [41].
Conclusion
Despite the use of antibiotics and vaccines, the frequency
of respiratory tract infections is still high and these infec-
tions interest a wide range of patients, from children to
aged people, including in particular these extreme categor-
ies because of the deficiency of their immune system, due
to immaturity in the former case and to “immunosenes-
cence” in the latter. For that reason immunostimulant
drugs are getting more important to prevent and to at-
tenuate infections.
Pidotimod (3-L-pyroglutamyl-L-thiazolidine-4carboxylic
acid) is a synthetic dipeptide with immunomodulatory
properties. Studies conducted in vivo on different popula-
tions and mice and also in vitro studies show its efficacy
and safety. The outcomes considered are both clinical and
laboratory parameters.
In vivo studies have been conducted on:
– children with and without lower or upper
respiratory tract infections (also recurrent)– a restricted population of children with Down’s
Syndrome which are often affected by acute
respiratory tract infections
– children and adults with asthma, in which
respiratory tract infections can lead to a worsening
of the disease
– children with immunological disorders, such as
Henoch-Schonlein Purpura, or with nephrotic
syndrome
– adults with persistent or recurrent upper and lower
respiratory tract infections (such as pneumonia and
pharyngotonsillitis) and healthy adults
– adults with genital or urological infections (in
particular HPV) or affected by chronics hepatitis C
– adults with COPD exacerbations
The common end-point of these studies is that
Pidotimod has an immunomodulatory activity which is
able both to improve the clinical conditions of patients
and to enhance and stimulate their immunity cells
(lymphocytes but not only) functions acting on adap-
tive and innate immunity. Pidotimod is also able to in-
crease the concentration of salivary IgA directed
against bacteria; furthermore, it can modulate airway
epithelial cells functions up-regulating the expres-
sion of toll-like receptors and acting on adhesion
molecules. Studies remark that also the balance of
intestinal flora can influence the immunity in respira-
tory mucosa, remembering the role of probiotics and
immunostimulants.
According to studies conducted on patients with
atopic asthma, it seems that Pidotimod could affect
T-lymphocytes balance with a possible addictional
anti-allergic activity. Furthermore, it has been demon-
strated an improvement of FEV1 and PEF in asthmatic
patients treated with Pidotimod.
Main clinical outcomes are the reduction of the num-
ber of infectious episodes, lesser severity of signs and
symptoms and, consequently, a reduction in use of anti-
biotics and symptomatic drugs, less working and school
days lost, less mortality and morbidity.
The studies considered give positive results, confirm-
ing Pidotimod’s efficacy, even when compared to other
immunostimulants or combined with antibiotic therapy.
Furthermore, many studies show a good safety profile of
the drug, without recording serious adverse events and
mutagenic potential, and a very low incidence of side ef-
fects. Pidotimod is also a more safe solution in patients
subjected to vaccination, if compared to lyophilized poli-
bacterial, which can’t be administered for thirty days be-
fore vaccination.
Finally, we must remember that pharmacokinetic stud-
ies demonstrated that different oral formulations (such
as tablets, sachets and vials) are bioequivalent.
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